. 2022 Mar 7;27(4):e328–e339. doi: 10.1093/oncolo/oyab041

Table 3.

Treatments for patients with advanced pheochromocytomas/paragangliomas and bronchial neuroendocrine tumors.

Tumor characteristics				Most appropriated treatment
Pheochromocytomas/paragangliomas	SSTR expression and MIBG positive	Progressing	Nonfunctional	MIBG ¹⁷⁷Lu-DOTATATE
Pheochromocytomas/paragangliomas	SSTR expression and MIBG positive	Progressing	Functional with uncontrolled hormonal symptoms	MIBG ¹⁷⁷Lu-DOTATATE SSAs
Bronchial NETs	G1-G2	Positive SSTR imaging	1^st line	SSAs
			2^ndline (progression to SSAs)	Everolimus ¹⁷⁷Lu-DOTATATE
			Positive FDG-PET-TC	Chemotherapy(temozolomide and capecitabine) Everolimus

Abbreviations: NETs, neuroendocrine tumors; G, grade; SSTR, somatostatin receptor; MIBG, meta-iodobenzylguanidine; FDG-PET-TC, 2-fluoro-2-deoxy-d-glucose-positron-electron tomography-computed tomography; SSAs, somatostatin analogs.